Comparing cognitive performance and brain imaging in dementia
Cognition and NeuroImaging in neuroDegenerative Disorders (CogNID)
This study is trying to see how thinking skills and brain scans differ between people with mild dementia, including Alzheimer's, and healthy individuals to help improve diagnosis and understanding of these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 125 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nottingham University Hospitals NHS Trust Academic / other |
| Locations | 2 sites (Nottingham, Easat Midland and 1 other locations) |
| Trial ID | NCT03861884 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare cognitive performance among participants with mild cognitive impairment or mild dementia, including Alzheimer's Disease, Vascular Cognitive Impairment, and Fronto-temporal Dementia. It will utilize ultra high-field MRI at 7T to identify differences in brain iron levels, resting oxygen usage, cerebral blood flow, and blood-brain barrier leakage among different dementia syndromes and healthy volunteers. The study seeks to establish distinct cognitive and imaging profiles that could aid in the diagnosis and understanding of these conditions.
Who should consider this trial
Good fit: Ideal candidates include individuals with mild cognitive impairment or mild dementia who have relevant biomarker evidence or clinical diagnoses.
Not a fit: Patients without the capacity to consent, those with learning disabilities, or contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance diagnostic accuracy and treatment strategies for various forms of dementia.
How similar studies have performed: Other studies have shown promise in using advanced imaging techniques to differentiate between types of dementia, suggesting this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Ability to give informed consent. 2. Either pathological, genetic or imaging biomarker evidence to suggest Fronto-temporal Lobar Degeneration, Alzheimer's Disease or Vascular Cognitive Impairment, or defined clinical diagnoses. Exclusion Criteria: 1. Lack of mental capacity to consent to study involvement. 2. Not speaking English before age 5 years. 3. Learning disability. 4. MRI contraindications
Where this trial is running
Nottingham, Easat Midland and 1 other locations
- Nottinghamshire Healthcare NHS Foundation Trust — Nottingham, Easat Midland, United Kingdom (Completed)
- Nottingham University Hospitals NHS Trust — Nottingham, East Midland, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Akram Hosseini, MD, PhD — Akram.Hosseini@nuh.nhs.uk
- Study coordinator: Akram Dr Hosseini
- Email: Akram.Hosseini@nuh.nhs.uk
- Phone: 0115 924 9924
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.